Large AI project receives over €95 million for ten years of public-private research23 September 2021
The Dutch Research Council (NWO) is to fund two consortia for a period of ten years. Radboudumc participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboudumc leads five of these eight labs.
ADOPT sub-biobank21 September 2021
In the multicenter clinical study ADOPT, 280 men with oligo-recurrent prostate cancer from 10 participating hospitals in the Netherlands are randomized to receive standard metastasis-targeted radiotherapy or metastasis-targeted radiotherapy in combination with 6 months of ADT.
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.
Vooijs award for Merel van der Stelt21 May 2021
Merel van der Stelt has won the Vooijs Award with her final research project 'Making prosthetic devices' in the 3D lab at the Masanga Hospital in Sierra Leone. This award goes to the most clinically relevant final research project in the Technical Medicine educational programmes in the Netherlands.
Vici grant for Michiel Vermeulen Reading the epitranscriptome15 April 2021
Michiel Vermeulen, theme Cancer development and immune defense, has been awarded a Vici grant from the Netherlands Organisation for Scientific Research (NWO), one of the largest personal scientific awards in the Netherlands.
Genetische pleister ‘remt’ blindheid in patiënten met Usher syndroom Leidse ProQR bouwt onderzoek Radboudumc verder uit14 April 2021
Het Leidse biotechbedrijf ProQR Therapeutics presenteerde deze week positieve resultaten van een klinische fase I/II studie met het molecuul QR-421a, een molecuul dat in de vroegste fase is ontwikkeld door onderzoekers van het Radboudumc
Assessment of research with material from an existing biobank.28 January 2021
If you want to perform research with material from a biobank and the initiation of this biobank has already been approved by the CMO Radboudumc, you only need to submit an application to the CMO Radboudumc for assessment in certain cases.
Financial regulation for sub-biobanks15 September 2020
Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.